Eli Lilly's stock is down this year, and its high valuation may be a big reason why.

Both have plenty to offer investors, but one has a better outlook.

LLY stock falls 6% after an HSBC downgrade flagged persisting U.S. pricing pressure, rising market competition and compounded tirzepatide risks, despite strong GLP-1 demand.

Eli Lilly shares are down 6% Tuesday and on pace for their worst day since February after an HSBC downgrade. The crux of HSBC ...

A US court has certified a nationwide third party payor class in a lawsuit involving Eli Lilly’s former diabetes drug Actos.

Eli Lilly (LLY) stock declined after HSBC downgrade to Reduce with $850 price target, citing obesity drug market risks and ...

The call, led by HSBC analyst Rajesh Kumar, saw the bank cut LLY’s price target to $850 from $1,070. HSBC believes the ...

HSBC analysts just slashed their recommendation on the world's most valuable pharmaceutical company, Eli Lilly, signaling a potential cooling period for the red-hot obesity drug trade that has come to ...

Eli Lilly (LLY) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over the ...

Trading in Eli Lilly and Company LLYis quiet on Wednesday. This follows yesterday's drop of almost 6%. The move was driven by a downgrade. But the selloff may be over. A reversal could even occur. The ...

Eli Lilly (LLY) stock is lower today, after HSBC downgraded it to "reduce" from "hold," citing an inflated obesity drug market ...

Eli Lilly (LLY) stock drops as HSBC downgrades the company warning that weight-loss drugmaker could be “priced to perfection.